Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2011
|
| Subjects: | |
| Online Access: | https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|